Previous 10 | Next 10 |
HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today annou...
HAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced that effective as of market open on January 29, 2021, its co...
Familiar names topped ARK Investment Management's actively-managed ETFs last quarter, while work-from-home stocks pulled down performance as enthusiasm for recovery stocks arrived with vaccine approvals.And in her note about Q4 performance, ARK CEO Cathie Wood said it looks like cyclical sect...
Genomics is evolving to be big and can lead to a disruption of healthcare and pharma industries. Cost reduction for gene editing and DNA sequencing makes it accessible and more commonly used. Latest climb in valuation of Genomic stocks doesn't tickle the potential in case of succe...
HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological therapeutic products, is pleased to announce the appointment of Ms. Maital Shemesh-R...
Pluristem Therapeutics (PSTI) perks 4% premarket on collaboration with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome ((ARDS)) associated with COVID-19 in Mexico.The Phase II...
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with...
Gainers: Greenwich LifeSciences (GLSI) +424%.Xenetic Biosciences (XBIO) +329%.Rocket Pharmaceuticals (RCKT) +79%.MTS Systems (MTSC) +52%.Cypress Environmental Partners (CELP) +46%.Intec Pharma (NTEC) +42%.ZW Data Action Technologies (CNET) +33%.Cardtronics (CATM) +33%.Editas Medicine (ED...
Gainers: Xenetic Biosciences (XBIO) +410%, Greenwich LifeSciences (GLSI) +289%, Rocket Pharmaceuticals (RCKT) +74%, Intec Pharma (NTEC) +64%, ViewRay (VRAY) +14%.Losers: Atossa Therapeutics (ATOS) -39%, Pluristem Therapeutics (PSTI)&...
Pluristem Therapeutics (PSTI) slumps 42% premarket in reaction to recommendation letter by the independent Data Monitoring Committee ((DMC)) of its global Phase III study for the treatment of critical limb ischemia ((CLI)).The clinical dataset was reviewed for safety and analys...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...